According to the experimental results of KEGG and PPI in network pharmacology and literature review, the TGF-β1/p38MAPK/NF-κB signaling pathway plays a significant role in GN activated by MSU [28–30]. The gene discussed is NFKB1; the disease is ganglioneuroma.